Fact Sheet 2 - Transitional Cycles

 

PDF printable version of this page (PDF 330KB)

Expanded and Accelerated Price Disclosure (EAPD) commences on 1 December 2010. On that date, three of the data collection cycles under the price disclosure program prior to 1 December 2010, will be in progress (still in the data collection phase of the cycle). These cycles will become known as the Transitional Cycles.

The table below outlines the current collection period for each of these cycles and the Transitional Cycle they will become:

Current Collection Period	Transitional Cycle
1 January – 31 December	1
1 May – 30 April	2
1 September – 31 August	3

This Fact Sheet will help you understand how these drugs will transition into the new processes and provisions of EAPD, including:

• which drugs will be in each Transitional Cycle;
• the timeframes for each Transitional Cycle; and
• how each Transitional Cycle merges into the Main Disclosure Cycle.

Transitional Cycle 1

Drugs in Transitional Cycle 1

The following Drugs currently disclosing for the data collection period 1 January to 31 December will form part of Transitional Cycle 1.

Drug	Manner of Administration
Alendronic acid	Oral
Ceftriaxone	Injection
Cisplatin	Injection
Fluconazole	Oral
Fluconazole	Injection
Fludarabine	Injection
Levodopa with Carbidopa	Oral
Naltrexone	Oral
Risperidone	Oral
Topiramate	Oral
Vancomycin	Injection

Timeframes for Transitional Cycle 1

The table below outlines the revised data collection and reporting periods for Transitional Cycle 1.

Current Collection Period	Transitional Cycle Data Collection Start & End	Reporting Periods1 (Excluding completed Reporting periods2)	Submission Deadlines3	Reduction Date Note this remains unchanged	Data collection flows into Main Cycle
1 January – 31 December	1 January 2010 – 30 September 2011 (21 months data collection)	1 October 2010 – 31 March 2011	12 May 2011	1 April 2012	1 October 2011
		1 April 2011 – 30 September 2011	11 November 2011

¹ Including incentive data.
² Under the price disclosure policy (prior to 1 December 2010), these drugs have completed reporting for the period of 1 January 2010 to 30 September 2010.
³ Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 1 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 1 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2011, with no gap in the data collection periods (as shown in the diagram below).

 

Transitional Cycle 2

Drugs in Transitional Cycle 2

The following Drugs currently disclosing for the data collection period 1 May to 30 April will form part of Transitional Cycle 2.

Drug	Manner of Administration
Carvedilol	Oral
Clopidogrel	Oral
Enalapril with hydrochlorothiazide	Oral
Gemcitabine	Injection
Irinotecan	Injection
Memantine	Oral
Paclitaxel	Injection
Sumatriptan	Oral
Vinorelbine	Injection

Timeframes for Transitional Cycle 2

The table below outlines the revised data collection and reporting periods for Transitional Cycle 2.

Current Collection Period	Transitional Cycle Data Collection Start & End	Reporting Periods1 (Excluding completed Reporting periods2)	Submission Deadlines3	Reduction Date Note this remains unchanged	Data collection fl ows into Main Cycle
1 May – 30 April	1 May 2010 – 30 September 2011 (17 months data collection)	1 November 2010 – 31 March 2011	12 May 2011	1 April 2012	1 October 2011
		1 April 2011 – 30 September 2011	11 November 2011

¹ Including incentive data.
² Under the price disclosure policy (prior to 1 December 2010), these drugs have completed reporting for the period of 1 May 2010 to 31 October 2010.
³ Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 2 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 2 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2011, with no gap in the data collection periods (as shown in the diagram below).

Transitional Cycle 3

Drugs in Transitional Cycle 3

The following Drugs currently disclosing for the data collection period 1 September to 31 August will form part of Transitional Cycle 3.

Drug	Manner of Administration
Alendronic acid with colecalciferol	Oral
Amisulpride	Oral
Azithromycin	Oral
Bicalutamide	Oral
Bisoprolol	Oral
Cabergoline	Oral
Cefalotin	Injection
Doxorubicin	Injection/Intravesical
Escitalopram	Oral
Famciclovir	Oral
Fosinopril with hydrochlorothiazide	Oral
Glucose	Injection
Levetiracetam	Oral
Meloxicam	Oral
Mitozantrone	Injection
Morphine	Oral
Ondansetron	Injection
Ondansetron	Oral
Oxaliplatin	Injection
Oxazepam	Oral
Oxybutynin	Oral
Perindopril with indapamide	Oral
Prochlorperazine	Oral
Sodium Chloride	Injection
Sodium Lactate Compound	Injection
Valproic acid	Oral

Timeframes for Transitional Cycle 3

The table below outlines the revised data collection and reporting periods for Transitional Cycle 3.

Current Collection Period	Transitional Cycle Data Collection Start & End	Reporting Periods7	Submission Deadlines8	Reduction Date Note this remains unchanged	Data collection flows into Main Cycle
1 September – 31 August	1 September 2010 – 31 January 2012 (13 months data collection)	1 September 2010 – 31 March 2011	12 May 2011	1 August 2012	1 February 2012
		1 April 2011 – 30 September 2011	11 November 2011
		1 October 2011 – 31 January 2012	13 March 2012

⁷ Including incentive data.
⁸ Noting that data submitted quarterly before 01/12/10 will still be included into WADP calculations for these transitional cycles.

How Transitional Cycle 3 merges into Main Disclosure Cycle

Once a brand has completed the data collection period for Transitional Cycle 3 it will merge into the next available Main Disclosure Cycle, commencing on 1 October 2012, with no gap in the data collection periods (as shown in the diagram below).

EAPD Transitional Cycle 3 process

 

 

 

Novemeber 2012